Quoin Pharmaceuticals Announces $50M Private Placement, Shares Surge

What happened

Quoin Pharmaceuticals Ltd. (QNRX) announced on August 27, 2026, that it entered into a securities purchase agreement with institutional and accredited investors for a private placement of American Depositary Shares (ADSs) and warrants, with gross proceeds of up to approximately $50.0 million.

The company expects to receive approximately $30.8 million at closing, expected on August 31, 2026, and up to an additional $19.2 million if investors exercise the accompanying ordinary warrants. Net proceeds at closing are estimated at about $29.0 million after fees and expenses.

In a related move, Quoin issued 222,574 ADSs to three investors, including two directors, to satisfy approximately $1,146,000 in accrued and unpaid interest on promissory notes from 2020. The company said the interest was not accounted for during a prior merger.

The stock closed up 21.92% at $6.285 on August 28, 2026, with volume of about 30.5 million shares, more than 123 times its average volume.

The filing

The company filed a Form 8-K with the SEC on August 28, 2026, reporting the private placement, the unregistered sale of equity securities, and other events. The 8-K is a current report used to notify investors of significant corporate events.

The private placement involves the sale of 6,305,300 ADSs (or pre-funded warrants in lieu thereof) and ordinary warrants to purchase up to 3,152,650 ADSs. Each ADS represents 35 ordinary shares of the Israeli company.

The combined purchase price for each ADS and accompanying warrant is $4.88. The ordinary warrants have an exercise price of $6.10 per ADS and are exercisable for up to five years, or until 30 days after the company announces that the primary endpoint has been met in a clinical trial for its lead product candidate, QRX003, for Netherton Syndrome.

The company also entered into registration rights, lock-up, and exchange agreements. The directors and officers agreed to a lock-up period of 90 days after closing or the effective date of a resale registration statement, whichever is later.

What this means

A private placement is a sale of securities to a select group of investors without a public offering. Here, the company is raising capital to fund operations, including research and development and completion of clinical development of QRX003 for Netherton Syndrome, a rare genetic skin disorder.

The warrants are options to buy more ADSs later at a set price. The pre-funded warrants have a nominal exercise price of $0.0001, meaning they are essentially already paid for; they are used to allow investors to buy shares without the same restrictions as a direct purchase. The ordinary warrants have an exercise price of $6.10, which is above the current trading price, so they would only be exercised if the stock rises above that level.

The unregistered sale means the securities are not registered with the SEC, but they are offered under an exemption (Rule 4(a)(2) and Regulation D) for qualified institutional buyers and accredited investors. The company is required to file a registration statement for resale of these shares within 30 days after closing.

The exchange agreements settle outstanding debt from 2020 promissory notes by issuing ADSs instead of cash, which conserves cash for operations. The lock-up agreements prevent insiders from selling their shares for a specified period, which can help stabilize the stock price after the offering.

The stock surge and high volume indicate investor reaction to the capital raise and the company's progress, but the filing does not explain the price movement beyond the announcement itself.